Medicine and Dentistry
Patient
100%
Non Small Cell Lung Cancer
49%
Therapeutic Procedure
41%
Symptom
36%
Severe Asthma
32%
Chemoradiotherapy
32%
Smoke
32%
Obesity
19%
Follow up
19%
Cells
18%
Lung Cancer
18%
Randomized Controlled Trial
18%
Morbidity
18%
Obstructive Sleep Apnea
17%
Spontaneous Remission
17%
Asthma
16%
Experience
16%
Epidermal Growth Factor Receptor
16%
Neurokinin 1 Receptor
16%
Respiratory Tract Inflammation
16%
Glucose
16%
Biological Product
16%
Catheter
16%
Sleep
16%
Pleura Effusion
16%
Pulmonary Edema
16%
Toxicity
16%
Albumin
16%
Patient with Asthma
16%
Cost-Effectiveness Analysis
16%
Nurse
16%
Systematic Review
16%
Chronic Obstructive Pulmonary Disease
16%
Hypersensitivity
16%
Lung
15%
Age
13%
Eosinophilic
11%
Particular Matter 2.5
10%
Recurrent Disease
10%
Pregnancy
10%
Male
9%
Receptor Gene
9%
Endothelial Cell
9%
Overall Survival
9%
Woman
8%
Quality of Life
8%
Clinical Assessment
7%
Polysomnography
7%
Screening
7%
Postcapillary Venule
7%
Immunology and Microbiology
Severe Asthma
54%
Human Respiratory Syncytial Virus
49%
Neutrophil Granulocyte
49%
Inflammation
44%
Mepolizumab
32%
Respiratory Syncytial Virus Infection
30%
Blood Plasma
22%
Mycoplasma pulmonis
18%
Cell Adhesion Proteins
18%
Omalizumab
16%
Alveolar Macrophage
16%
Characterization of Antibody
16%
CD18
14%
Granulocyte
14%
Antiserum
12%
Respiratory Mucosa
10%
Neutrophil
8%
Monocyte
7%